- On 27 June 2026, Ducommun Incorporated (NYSE:DCO) was removed from several Russell value and microcap indices while being added to a range of Russell small-cap and growth benchmarks, including the Russell 2000 Growth and Russell 3000 Growth indices.
- This reclassification toward growth-focused indices highlights a shift in how Ducommun is being categorized by index providers, which can meaningfully alter how quantitative and index-tracking investors gain exposure to the stock.
- Next, we will examine how Ducommun’s move from value and microcap indices into multiple growth benchmarks could reshape its investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 52 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
Ducommun Investment Narrative Recap
To own Ducommun today, you need to believe in its ability to convert a growing mix of aerospace and defense programs, higher-margin engineered products, and facility efficiency gains into more consistent profitability. The recent shift into Russell growth indices mainly changes who owns the shares rather than Ducommun’s day to day fundamentals, so it does not materially alter the near term focus on missile backlog execution or the key risk around commercial aerospace and defense budget cyclicality.
Among recent announcements, the upcoming VISION 2032 roadmap update stands out as most relevant. As Ducommun is recast into growth benchmarks, investors will likely pay closer attention to how this longer term plan supports higher engineered product content, targeted US$13 million in annual cost savings, and disciplined M&A using the new US$650 million financing facility, all of which tie directly into the growth and margin expansion story highlighted by the index reclassification.
Yet, against this growth oriented index shift, investors should still be aware that Ducommun’s exposure to commercial aerospace cycles and U.S. defense priorities could…
Read the full narrative on Ducommun (it’s free!)
Ducommun’s narrative projects $1.1 billion revenue and $134.3 million earnings by 2029.
Uncover how Ducommun’s forecasts yield a $164.00 fair value, a 12% downside to its current price.
Exploring Other Perspectives
Before this index news, the most pessimistic analysts were already cautious, assuming only about US$1.1 billion of revenue and US$108.6 million of earnings by 2029, so if you are weighing Ducommun’s reclassification into growth indices against that more restrained view of missile and aerospace tailwinds, it is worth recognizing how far opinions differ and considering how both narratives could evolve from here.
Explore 2 other fair value estimates on Ducommun – why the stock might be worth 12% less than the current price!
The Verdict Is Yours
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
Contemplating Other Strategies?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Source: Original Article




























